Dynavax to Present at BIO CEO & Investor Conference February 24, 2005
BERKELEY, Calif., Feb 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President and CEO, will discuss the Company's approaches to treat allergy and asthma during a focus session, entitled "Breathtaking New Respiratory Drugs for COPD, Asthma and Allergies," at the BIO CEO & Investor Conference 2005 in New York City. The focus session will take place at 4:00 pm ET in the Duke of Windsor room of the Waldorf-Astoria Hotel.
The focus session will be webcast as a 24-hour delayed replay starting at 4:00 p.m. ET on Friday, February 25, 2005. The webcast presentation may be accessed by visiting, http://www.corporate- ir.net/ireye/confLobby.zhtml?ticker=28873&item_id=1009769 .
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three initial indications: ragweed allergy immunotherapeutic, currently in a Phase 2/3 clinical trial; a hepatitis B vaccine, currently in a Phase 2/3 clinical trial; and an asthma immunotherapeutic that has completed a Phase 2 exploratory trial.
SOURCE Dynavax Technologies
Jane M. Green, Ph.D., Vice President, Corporate Communications, Dynavax Technologies
+1-510-665-4630, or jgreen@dvax.com
http://www.prnewswire.com